Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Targets Migraine, Schizophrenia And Opioid Sparing Drugs For Clinical Outcome Assessment Development

Feb 26 2019

• By Derrick Gingery

Doctor holding blue crystal ball with pain sign on medical background.

Related Content

US FDA's New Development Science Office Modeled On Modeling Office

Jan 13 2019

Patient-Focused Drug Development: US FDA 'Needs To Be Brave,' Tell Sponsors What Works Best

Oct 29 2018

FDA’s Woodcock Cautions Efforts To 'Legislate A New Generation Of Biomarkers'

Oct 22 2015

FDA's 21<sup>st</sup> Century Cures Plan Gives Patient-Focused Drug Development A Boost

Jul 10 2017

Opioid-Sparing Claims May Be Better Suited For Phase IV Trials Instead Of Phase III

Dec 12 2018

US FDA Mulling Core Criteria For Patient-Reported Outcomes

Nov 02 2018

US FDA’s Patient Input Guidance Opens Door Wider To Social Media Data Collection

Jun 19 2018

Drug/Software Combos Likely Won't Require Pre-Market Review By US FDA

Nov 20 2018

Additional Topics

United States Clinical Trials Research & Development FDA Regulation BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window